PorTal Access, Inc., a medical device company focused on improving vascular access for oncology patients, has appointed veteran life sciences executive David Snow to its Board of Directors. The company is currently advancing Flexi Port SLF TANL, a next generation chemotherapy port created to help reduce complications and enhance patient care across hospital, bedside, and outpatient environments. Snow’s addition to the board comes at a time when PorTal Access is preparing to move its technology forward and expand its strategic footprint in the oncology device market.
Health Technology Insights: Nemluvio Shows Rapid Itch Relief and Sleep Benefits
David Snow brings more than forty years of leadership experience across biotechnology and global pharmaceutical organizations. Before retiring from Regeneron in 2025, he led the company’s Commercial Immunology business. In that role, he directed commercial strategy and market execution for Dupixent dupilumab in the United States and internationally. During his tenure, Dupixent grew to become the most prescribed biologic among dermatologists and developed into one of the largest and fastest growing biologic therapies worldwide. Snow also played a key role in broadening Regeneron’s commercial presence in Europe, Japan, and Canada, helping establish strong international operations.
Earlier in his career, Snow held senior leadership positions in both emerging biotechnology firms and major pharmaceutical companies. He spent fifteen years at AstraZeneca, including serving as President of AstraZeneca China, where he helped transform the region into the company’s second largest market with significant growth momentum. Over the course of his career, he has built commercial teams, guided product launches, and expanded market access strategies at organizations such as Bristol Myers Squibb and Searle. Snow earned a Bachelor of Business Administration from Auburn University and an MBA from the NYU Stern School of Business.
Angela Dotson, Executive Vice President of Business Development and Head of U.S. Operations at PorTal Access, Inc., said the company is pleased to welcome Snow to the board at a pivotal stage of development. She noted that his depth of experience in global commercialization, operational execution, and scaling innovative healthcare products closely aligns with the company’s objectives. Dotson added that his perspective will help guide PorTal Access as it advances Flexi Port and works to improve clinical outcomes and quality of life for people undergoing cancer treatment.
Health Technology Insights: FDA Approves Exdensur (Depemokimab) for Severe Asthma
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
